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Definition, Classification, and 
Burden of Epilepsy
Joseph Nelson Siewe Fodjo
Abstract
Epilepsy is one of the most common neurological diseases in the world, and is 
characterized by recurrent unprovoked seizures (fits) that can occur at all ages. 
The causes of epilepsy are multiple, ranging from perinatal problems, traumatic 
brain insults, metabolic abnormalities, to infections of the central nervous system; 
sometimes, the causes are not known. Consensual international norms have been 
established for the proper diagnosis and management of epilepsy, including speci-
ficities for vulnerable populations such as children and pregnant women. Specific 
emphasis must be laid on low and middle income countries, where about 80% of all 
persons with epilepsy reside. In such resource-limited settings, epilepsy patients are 
often confronted with sub-optimal care, reduced access to treatment, and frequent 
epilepsy complications. Early epilepsy diagnosis and proper anti-epileptic treat-
ment usually result in satisfactory seizure control, and enable persons with epilepsy 
to lead a normal life. Besides the usual medications, psychosocial support and 
stigma reducing interventions are crucial to improve the quality of life of affected 
persons and their families.
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1. Introduction
Epilepsy is a chronic disease of the brain estimated to affect 50 million people 
worldwide according to World Health Organization (WHO) [1]. It is character-
ized by repetitive, unprovoked epileptic seizures which vary widely in their clini-
cal presentations. Although a meticulous patient history complemented by sound 
clinical/paraclinical investigations often unveil the underlying cause of epilepsy, 
the exact etiology remains unknown in about half of cases [2]. Proper diagnosis 
and treatment of epilepsy are paramount to achieve seizure control and ensure an 
optimal quality of life for affected individuals.
1.1 Definition of epilepsy
In 2005, the International League Against Epilepsy (ILAE) defined epilepsy as 
“a disorder of the brain characterized by an enduring predisposition to generate 
epileptic seizures, and by the neurobiologic, cognitive, psychological, and social 
consequences of this condition” [3]. An epileptic seizure, on the other hand, 
refers to “a transient occurrence of signs and/or symptoms due to abnormal exces-
sive or synchronous neuronal activity in the brain” [3]. While these definitions 
remain very conceptual, they are difficult to apply in a real-life clinical setting. 
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Therefore, a Task Force was commissioned to formulate an operational definition 
of epilepsy; the definition of epilepsy was thus broadened to accommodate three 
practical circumstances (Box 1) [4].
Emphasis must be laid on some points in this operational definition. Firstly, the 
seizures must be unprovoked, and not as a result of an acute, punctual event such 
as head trauma, substance abuse/withdrawal, metabolic imbalance, infection of the 
central nervous system or fever. As concerns the minimal risk of recurrence fixed 
at 60%, it is merely approximative of the likelihood of future seizure (mostly based 
on paraclinical findings on the electroencephalogram (EEG) or brain imaging [5]) 
and should not be interpreted as an absolute cut-off [4]. Another point to note is the 
minimal time difference of 24 hours between the seizures, but without a maximum 
time interval; in practice, the ILAE maintains the lifetime occurrence of two unpro-
voked seizures as a diagnostic criterion for epilepsy. Finally, epilepsy syndromes 
have been elaborately documented by the ILAE; each syndrome is characterized by 
specific electroclinical and/or genetic features [6].
1.2 Diagnosis of epilepsy
The diagnosis of epilepsy is essentially clinical. Based on the criteria listed in 
Box 1, the epilepsy diagnosis can be made if an individual fulfills the ILAE crite-
ria. In a hospital setting, the following paraclinical workups can be performed to 
further investigate the epilepsy diagnosis: EEG, brain imaging (by scan or magnetic 
resonance), and blood tests (to investigate metabolic or genetic epilepsies).
In field research settings, the ILAE recommends epilepsy assessment using a 
door-to-door approach [7]. Several tools have been developed for epilepsy screen-
ing during epilepsy studies [8–11]; for studies conducted in the sub-Saharan setting 
in particular, the Institute of Neurological Epidemiology and Tropical Neurology of 
Limoges (France) developed a questionnaire with the support of the Pan-African 
Association of Neurological Sciences and the ILAE (Commission on Tropical 
Diseases, 1993–1997) [11]. This questionnaire was validated in Mauritania (sensitiv-
ity: 95.1%; specificity: 65.6%) and has since then been widely used for epilepsy sur-
veys in Africa [11]. It has the advantages of being brief, usable by non-physicians, 
and diagnosing seizure types other than generalized tonic-clonic episodes (for 
instance, absences and focal seizures). To ensure accurate outcomes, it is important 
that a neurologist or physician trained in epilepsy confirms all suspected epilepsy 
cases clinically, following the ILAE diagnostic criteria.
Epilepsy is a disease of the brain defined by any of the following conditions:
• At least two unprovoked (or reflex) seizures occurring >24 h apart
• One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence 
risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years
• Diagnosis of an epilepsy syndrome
Epilepsy is considered to be resolved for individuals who had an age-dependent epilepsy syndrome 
but are now past the applicable age or those who have remained seizure-free for the last 10 years, with no 
seizure medicines for the last 5 years.
Box 1.
 Operational (practical) clinical definition of epilepsy [4].
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1.3 Epidemiology and burden of epilepsy
Although epilepsy occurs in a ubiquitous manner, its burden is unevenly spread 
in different regions of the world depending on the local distribution of risk factors, 
access to treatment, and population demography. A recent meta-analysis found an 
overall lifetime prevalence of epilepsy of 7.60 per 1000 population (95% CI 6.17–
9.38); this was higher in low and middle income countries (LMICs) (8.75 per 1000; 
95% CI 7.23–10.59) than in high income countries (5.18 per 1000; 95% CI 3.75–7.15) 
[12]. A similar pattern was observed regarding epilepsy incidence: it was higher in 
LMICs compared to high-income countries, 139.0 per 100,000 person years (95% 
CI 69.4–278.2) vs. 48.9 per 100,000 person years (95% CI 39.0–61.1) [12].
These numbers clearly demonstrate that epilepsy poses a greater problem among 
populations living in LMICs compared to those in industrialized countries [2]. 
Indeed, nearly 80% of the global burden of epilepsy occurs in the people living in 
LMICs [1]. In sub-Saharan Africa specifically, a median epilepsy prevalence of 14.2 
per 1000 (IQR 8·0–33·2) was documented, with over 90% of cases being younger 
than 20 years [13]. Annual epilepsy incidence was also high, reaching 81.7 per 
100,000. Mortality was greatest in the 18–24 years age group, suggesting a relatively 
low life expectancy among persons with epilepsy (PWE) in Africa [13]. Suggested 
explanations for this pattern include the epilepsy risk factors that are often reported 
in resource-poor settings such as perinatal brain insults, traumatic head injury and 
infections of the central nervous system [13]. A variable genetic predisposition to 
manifest seizures in different populations may also explain the regional disparities 
observed in the occurrence of epilepsy worldwide, as people of different ethnic 
origins within a given population were found to have different incidence rates for 
epilepsy [14].
According to the 2016 Global Burden of Disease Collaborators, epilepsy 
accounted for >13 million Disability Adjusted Life Years (DALYs – a measure of 
the number of years of healthy life lost to epilepsy within a given population), and 
was responsible for 0.5% of the total disease burden in 2016 [15]. Again, important 
geographical differences were noted with epilepsy ranking among the top five 
neurological diseases in low-income regions. That study also found significant 
reductions in mortality and DALY among PWE between 1990 and 2016, reflecting 
some improvement in epilepsy healthcare and treatment.
2. Seizure/epilepsy classification and etiologies
International standards and norms have been adopted to classify seizures and 
epilepsies.
2.1 Classification of seizures
In 2017, the ILAE released the most recent guidelines for classifying seizures 
and epilepsies [5, 6, 16, 17]. Seizure classification begins with the mode of onset, 
whether focal or generalized [16]; the onset may also be unknown if the patient/
caregiver does not recall the details of the initial seizure manifestations. Focal-onset 
seizures are further categorized into two depending on the state of consciousness 
during any part of the seizure: retained awareness versus impaired awareness 
(Figure 1) [16]. Irrespective of whether the onset is focal or generalized, seizures 
are grouped based on their physical manifestations as being motor (visible exter-
nal movements) or non-motor (Figure 1). There is also a special group for focal 
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onset seizures which evolve to generalized seizures, known as focal to bilateral 
tonic-clonic seizures [16]. Of note, absence seizures are considered as generalized 
non-motor seizures [16]. However, in case some seizure descriptions do not appro-
priately fit into any of these categories, they can be considered as “unclassified”.
2.2 Classification of epilepsies
For epilepsies, the classification starts with the seizure type [6], and the certainty 
that the nature of the seizure(s) justifies the diagnosis of epilepsy [4]. Patients who 
do not meet criteria for epilepsy (for example, a single seizure or repeated provoked 
seizures) should be classified as to a seizure type, but classification should stop there 
[5]. Once the epilepsy diagnosis is confirmed, the epilepsy type can be deduced as 
focal, generalized, combined generalized & focal, or unknown (Figure 2) [6]. The 
epilepsy type is decided mainly on clinical grounds, and the diagnosis may be sup-
ported by EEG findings [6]. The final (facultative) level in epilepsy classification is 
the epilepsy syndrome diagnosis; an epilepsy syndrome refers to a cluster of features 
incorporating seizure types, EEG results, and brain imaging features that tend to 
occur together [6]. Each epilepsy syndrome often has specific features such as age 
at onset and remission (where applicable), seizure triggers, diurnal variation, and 
sometimes prognosis. Distinctive co-morbidities such as intellectual and psychiatric 
abnormalities may also be associated with specific epilepsy syndromes, as has been 
observed with the nodding syndrome [18]. Other common epilepsy syndromes 
include: Childhood Absence Epilepsy, Juvenile Absence Epilepsy, Juvenile Myoclonic 
Epilepsy, and Generalized Tonic-Clonic Seizures Alone; these are all forms of 
idiopathic generalized epilepsies [6]. Classification of epilepsy into syndromes often 
has etiologic, prognostic, and treatment implications [6].
A new feature in the 2017 epilepsy classification is that it integrates an etiology 
component as well as co-morbidities in epilepsy (Figure 2). Six etiological axes 
were enumerated by the ILAE task force: structural, genetic, infectious, metabolic, 
Figure 1. 
ILAE 2017 classification of seizure types (extended version) [16] (used with permission).
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immune, and unknown etiologies. Co-morbidities which should be considered 
on a case-by-case basis when diagnosing/classifying epilepsy include: intellectual 
decline, psychiatric and behavioral abnormalities, psychosocial problems, sleep 
disorders, and motor deficits [6].
2.3 Epilepsy etiologies
2.3.1 Structural etiologies
These are caused by structural brain abnormalities which have been shown to 
substantially increase the risk of developing epilepsy. These abnormalities are usu-
ally detectable by neuroimaging and in association with electroclinical assessments, 
lead to a reasonable inference that they are responsible for the enduring predisposi-
tion to unprovoked seizures [3, 6]. Structural etiologies could be primitive (for 
instance congenital malformations), or acquired (from a stroke, head trauma, 
infection, hypoxic-ischemic encephalopathy) [6].
2.3.2 Genetic etiologies
Epilepsy etiology is considered as genetic if there exists a specific disease-causing 
variant in a gene or copy number variant, believed to be the explanation for the 
observed epileptogenicity [5]. Of note, genetic mutations are not always inherited, as 
several epileptogenic de novo mutations have been identified [6]. The genetic altera-
tion often causes a very heterogeneous phenotypic spectrum. A few genetic epilepsies 
identified to date include: the syndrome of Benign Familial Neonatal Epilepsy (KCNQ2 
or KCNQ3 mutations) [19] and the Dravet syndrome (SCN1A mutations) [20].
2.3.3 Infectious etiologies
These are the most common preventable causes of epilepsy, particularly in sub-
Saharan Africa [13, 21]. The concept of an infectious etiology is that the epilepsy 
Figure 2. 
ILAE framework for the classification of epilepsies [6] (used with permission).
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directly results from a known infection in which seizures are a core symptom [6]; 
it is the persistence of these seizures even after resolution of the acute infection 
that is referred to as epilepsy of infectious origin. Common examples of infectious 
etiologies include neurocysticercosis, tuberculosis, HIV, cerebral malaria, subacute 
sclerosing panencephalitis, cerebral toxoplasmosis, and congenital infections 
such as Zika virus and cytomegalovirus [6, 22]. A recent cohort study supports 
the addition of onchocerciasis to this list, as the more infected participants had an 
increased risk of developing epilepsy later in life [23]. These infections sometimes 
have a structural correlate to explain the seizure recurrence even after anti-infec-
tious treatment; this results in a substantial overlap with the acquired structural 
causes of epilepsy [5].
2.3.4 Metabolic etiologies
In some cases, the core cause of the epilepsy results from a metabolic derange-
ment. Clinical entities such as porphyria, uremia, aminoacidopathies, or pyridox-
ine-dependent seizures all fall within this category. These conditions may also be 
associated with a pre-existing genetic defect, although a few can be acquired such as 
cerebral folate deficiency [6].
2.3.5 Immune etiologies
There are a rising number of persons in whom the epilepsy is caused by 
an autoimmune condition, as evidenced by an autoimmune-mediated central 
nervous system inflammation [6]. Examples include anti-NMDA (N-methyl-
D-aspartate) receptor encephalitis and anti-LGI1 encephalitis [24]. The anti-
leimodin antibodies hypothesis for central nervous system damage would equally 
place Nodding syndrome in this category [25].
2.3.6 Unknown etiology
For many PWE, the exact etiology may not be known. In such cases, diagnosis 
and management are solely based on electroclinical findings [6]. Nevertheless in 
some settings, epidemiological observations may provide clues as to a possible 
epilepsy etiology within a given vicinity. For instance, a pooled analysis of 37 stud-
ies showed that the etiologic fraction of epilepsy was estimated to be 63.0% (95% 
CI: 61.4 ± 64.5) in persons exposed to cysticercosis [26]. Therefore, in cysticercosis-
endemic settings, it would be reasonable to assume that a considerable number of 
epilepsy cases are due to neurological complications of Taenia solium infection even 
without laboratory confirmation. Similarly, in onchocerciasis-endemic villages 
of Cameroon, the contribution of infection with O. volvulus to epilepsy was very 
high (population-attributable fraction: 91.7%, 95% CI 56.7–98.4; p = 0.0021) [23]. 
Hence in communities with proven high ongoing transmission of O. volvulus, many 
epilepsies of “unknown” etiology could as well be caused by onchocerciasis.
3. Epilepsy management in specific settings
About four fifth of PWE currently reside in LMICs where epilepsy care is 
often sub-optimal, resulting in a 75% treatment gap (proportion of PWE needing 
treatment who do not receive the necessary anti-epileptic drugs) [1]. It is therefore 
important to discuss epilepsy in these contexts, and propose ways to improve PWE 
management in such settings. Another special population worth looking into is the 
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women of reproductive age suffering from epilepsy. The risk with these women is 
the teratogenic effects of anti-epileptic drugs, which renders their management 
before, during, and after pregnancy quite delicate.
3.1 Managing epilepsy in resource-limited settings
Improved management of PWE in resource-limited settings may be achieved 
by decentralizing epilepsy care. Approaches to diagnose and manage epilepsy and 
related complications can be simplified and taught to non-physicians, who will be 
in charge of running local epilepsy clinics under the supervision of physicians or 
specialists [27, 28]. Setting up a community-based epilepsy surveillance system will 
enable early diagnosis and treatment of PWE thereby preventing complications. 
To reduce the treatment gap, a regular supply of subsidized anti-epileptic drugs 
(AEDs) appropriate for different seizure types should be instituted. Daily intake 
of the adequate AEDs would eventually achieve seizure control in at least 70% of 
PWE [1]. The first-line AEDs that are routinely used in sub-Saharan Africa include 
phenobarbital, carbamazepine, phenytoin, and valproate [29]. Their indications 
and prescribed dosages as recommended by the WHO are detailed in Table 1 [30]. 
AED treatment must be initiated as monotherapy with progressive dose increase 
based on the response to the treatment and seizure control. Phenobarbital, the most 
available and affordable AED (annual cost per PWE: 5 US dollars [29]), is used as 
first-line treatment for most seizure types but is not recommended for absences. 
It is usually initiated at 2–3 mg/kg/day and could be increased every 2–3 weeks by 
15 mg if seizures continue, without going above the maximal recommended dose. 
When switching to another AED, phenobarbital should be tapered progressively 
(15 mg reduction every 2 weeks) while starting the newly prescribed AED as soon 
as the tapering begins. This approach minimizes the risk of rebound seizures upon 
stopping phenobarbital [31].
Besides the AEDs in Table 1 which are commonly used in resource-limited 
settings, newer AEDs have been developed and are widely used in high-income 
countries; these include: gabapentin (GBP), topiramate (TPM), lamotrigine 
(LTG), levetiracetam (LEV), rufinamide (RFN), vigabatrin (VGB), oxcarbazepine 
(OXC), perampanel (PER), lacosamide (LCM) and eslicarbazepine acetate [36]. 
Although these are more expensive and less available in LMICs compared to the 
routine first-line AEDs, they are superior in achieving seizure control with rela-
tively less side effects and fewer drug interactions.
Another essential component of epilepsy care in resource-limited settings is 
stigma reduction. In rural communities of Africa, PWE and their families are often 
stigmatized as a result of misconceptions regarding the origin and transmissibility 
of epilepsy [37]. Therefore, it is important that community awareness programs on 
epilepsy, as well as other interventions should be implemented to reduce stigma and 
facilitate the social rehabilitation of PWE [38].
3.2 Epilepsy in women of child-bearing age
In addition to seizures and related complications experienced by all PWE, 
women with epilepsy (WWE) require a more comprehensive management strat-
egy that takes into account reproductive health needs [39]. Indeed, optimal sei-
zure control is recommended to ensure positive health and gestational outcomes 
for these women. However, most of the first-line AED routinely used in Africa 
(Table 1) may reduce the efficacy of hormonal contraceptives [40] or increase 
the risk for foetal malformations if taken during pregnancy [41]. Therefore, a 
tailored management approach is recommended for WWE and should include 
Epilepsy
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Drug Indication and 
frequency of use
Required dosage Remark
Children Adults
Phenobarbital Recommended 
by WHO as first 
line AED for 
most seizure 
types, except 
absences; cheap 
and readily 
available [30, 32]. 
Used by 74.6% of 
PWE [33].
Given once or 
twice daily
Starting dose:
2–3 mg/kg/day
Maintenance:
3–6 mg/kg/day
Given once 
daily
Starting dose:
60 mg/day
Maintenance:
60–180 mg/day
Steady state 
reached after 
14–21 days. Possible 
side effects: 
Drowsiness, skin 
rash, lethargy and 
hyperactivity in 
children, hepatic 
failure, Stevens 
Johnson syndrome
Carbamazepine Indicated for 
focal seizures, 
and could 
be used in 
generalized 
convulsive 
seizures [31]. 
Used by 27.4% of 
PWE [33]
Given twice 
daily
Starting dose:
5 mg/kg/day
Maintenance:
10–30 mg/kg/
day
Given twice 
daily
Starting dose:
100–200 mg/
day
Maintenance:
400–1400 mg/
day
Steady state 
reached in 8 days. 
Possible side 
effects: allergic 
skin reactions, 
bone marrow 
suppression 
with long-term 
use, blurred 
vision, diplopia, 
ataxia, nausea. 
Contraindicated 
in absences and 
myoclonus [31]
Phenytoin Indicated for 
treating some 
generalized 
seizures 
and status 
epilepticus [34]. 
Used by 22.2% 
of PWE [33]
Given once/
twice daily
Starting dose:
3–4 mg/kg/day
Maintenance:
3–8 mg/kg/day 
(max 300 mg 
daily)
Given once or 
twice daily
Starting dose:
150–200 mg/
day
Maintenance:
200–400 mg/
day
Possible side 
effects: drowsiness, 
ataxia, slurred 
speech, motor 
twitching and 
mental confusion, 
coarsening of facial 
features, hepatitis, 
gum hyperplasia, 
hirsutism, skin 
reaction including 
Stevens Johnson 
syndrome
Valproate Broad spectrum 
anticonvulsant 
that can be used 
for both focal 
and generalized 
onset seizures. 
Specifically 
indicated for 
absence, atonic 
and myoclonic 
seizures [34]. 
Preferred drug 
for nodding 
seizures [35]. 
Used by 14.7% 
of PWE [33]
Given twice 
daily
Starting dose:
5–10 mg/kg/
day
Maintenance:
15–30 mg/kg/
day
Given twice 
daily
Starting dose:
400 mg/day
Maintenance:
400–2000 mg/
day
Possible side effects: 
sedation, tremor, 
transient hair loss, 
increase in body 
weight, impaired 
hepatic function. 
Use in women of 
childbearing age is 
discouraged
Table 1. 
Description of common first-line AEDs in resource-limited settings.
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the following components: regular evaluation of the treatment regimen/dose and 
adjustments if needed; contraception and pre-conceptual counseling; psychoso-
cial support and stigma-reducing interventions to improve their self-esteem and 
quality of life [42].
4. Public health interventions for epilepsy
The high epilepsy burden, unequaled treatment gap, and low quality of life of 
PWE in low-income settings have been a global health concern during the pass 
decades. Following the launching of the Global Campaign Against Epilepsy in the 
early 2000s by the International League Against Epilepsy (ILAE) and International 
Bureau for Epilepsy (IBE), a number of epilepsy demonstration projects which used 
a primary healthcare approach were launched in five developing countries: China, 
Senegal, Zimbabwe, Brazil, and Argentina [43, 44]. In 2015, epilepsy was acknowl-
edged as a major public health problem during the 68th World Health Assembly, 
and participating countries engaged to step care up epilepsy care [45]. Eventually, 
the Mental Health Gap Action Programme (mhGAP) enabled the development of 
evidence-based guidelines for managing neurological conditions including epilepsy 
in resource-limited settings [30].
Outcomes from the various demonstration projects [46] as well as more recent 
studies in Guinea [28] and South Africa [47] are in favor of a community-based 
approach whereby local non-specialized staff and community health workers cater 
for the PWE. Phenobarbital, a cheap and available first-line AED, is the WHO’s 
recommended molecule of choice for large scale epilepsy treatment [48]. Another 
important public health component in epilepsy is education and information 
campaigns, aimed at reducing the epilepsy-related stigma and its consequences on 
the quality of life of the PWE [32, 46].
5. Conclusion
Epilepsy remains a common neurological disorder with a wide clinical 
spectrum and a panoply of etiologies. Consensual diagnostic and therapeutic 
approaches have been established for epilepsy and they constantly evolve as more 
aspects of this condition are being uncovered by science. LMICs are the most 
affected by epilepsy, and should therefore be prioritized for interventions aimed 
at reducing the epilepsy burden.
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